MMWR LTD

Meet MMWR LTD.

We offer a groundbreaking solution for early cancer detection, addressing critical gaps in current diagnostics.Raise money to finalize product development, start production, obtain regulatory approvals, launch the product to market.Join us in revolutionizing women’s healthcare and making a significant impact on global health outcomes.

The Team

Prof Igor Goryanin

Mrs Irina Goryanin

About Us

Igor Goryanin, is the co-founder of MMWR.  He currently holds the Henrik Kacser Chair in Systems Biology at the University of Edinburgh and is an Adjunct Professor, Okinawa Institute of Science and Technology, Japan. Professor Goryanin is an award-winning researcher with a successful career that crosses the worlds of academia and business. 

Problem

Access to expensive diagnostic methods (mammogram; CT scan) to combat the continuing high mortality rates from cancer, including variants which are traditionally difficult to diagnose. Early detection can reduce the mortality but in 2022, there were 2.3 million breast cancer cases worldwide, and 670,000 deaths, and some cancers, like Ovarian, are difficult to detect which means that over 70% are diagnosed at an advanced stage. Traditional diagnostic methods are expensive and expose patients to radiation. In addition, over 3 billion people live in areas with limited access to essential health service. In many Low Middle Income countries, access to advanced diagnostic tools is limited. Rural areas in high-income countries also face significant disparities in access to cancer screening and diagnostic services.

Solution

Non-invasive handheld sensor using Passive Medical Radiometry (MWR) and AI for early cancer detection.Measures internal body and skin temperatures to detect malignant changes before structural changes occur.

Addresses a gap in the cancer diagnostics market by offering a safer, affordable, and accessible alternative to traditional methods.

Market

Our target customers are private clinics, women at risk of breast and ovarian cancers, particularly those with identified genetic mutations (e.g., BRAC1, BRAC2), and women in underserved and remote areas with limited access to traditional diagnostics. Later after receiving we will target NHS, etc.

This article was published on